Expert Interview
Discussing the potential of BNT327, a bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization, in development by BioNTech and the results presented at the ESMO Congress in patients with NSCLC
Ticker(s): BNTXInstitution: Self-employed
- Board Certified Hematologist and Medical Oncologist in private practice since 2011
- treats 25 patients for B-Cell Non-Hodgkin’s Lymphoma, 10 of whom have the diffuse large B-cell lymphoma (DLBCL) subtype
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
